Alpa Laboratories Limited
NSE: ALPA BSE: ALPA
NSE
104.55
4.10 (4.08%)
Prev Close
100.45
Open Price
101
Volume
99,639
Today Low / High
99.06 / 107.81
52 WK Low / High
83 / 144.5
Range
99 - 110
BSE
104.34
3.73 (3.71%)
Prev Close
100.61
Open Price
95.1
Volume
20,436
Today Low / High
95.1 / 107.32
52 WK Low / High
82.2 / 144.6
Range
99 - 110
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 104.55 (target range: 99 - 110), reflecting a change of 4.1 (4.08163%). On the BSE, it is listed at 104.34 (target range: 99 - 110), showing a change of 3.73 (3.70738%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
09 Jun
100.52
-0.54%
06 Jun
98.65
0.40%
05 Jun
100.50
-2.84%
04 Jun
100.55
0.32%
03 Jun
100.00
1.58%
Alpa Laboratories Limited Graph
Alpa Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alpa Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 104.55, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 104.34 | 105.38 | 94.85 - 115.92 |
| 106.43 | 85.14 - 127.71 | ||
| 107.47 | 75.23 - 139.71 | ||
| Bearish Scenario | 104.34 | 103.30 | 92.97 - 113.63 |
| 102.25 | 81.80 - 122.70 | ||
| 101.21 | 70.85 - 131.57 |
Overview of Alpa Laboratories Limited
ISIN
INE385I01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
41,581
Market Cap
2,103,428,782
Last Dividend
0
Official Website
IPO Date
2007-08-06
DCF Diff
36.62
DCF
63
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 108.74 Cr | 89.85 Cr | 18.89 Cr | 0.1737 | 0.00 Cr | 1.57 Cr | 6.15 Cr | 16.78 Cr | 8.01 | 23.00 Cr | 0.1543 |
| 2023-03-31 | 92.41 Cr | 61.67 Cr | 30.74 Cr | 0.3327 | 0.00 Cr | 1.10 Cr | 7.34 Cr | 12.58 Cr | 5.98 | 17.44 Cr | 0.1362 |
| 2022-03-31 | 110.51 Cr | 76.11 Cr | 34.41 Cr | 0.3113 | 0.00 Cr | 1.72 Cr | 9.54 Cr | 14.09 Cr | 6.70 | 21.43 Cr | 0.1275 |
| 2021-03-31 | 96.41 Cr | 64.76 Cr | 31.66 Cr | 0.3284 | 0.00 Cr | 2.20 Cr | 9.72 Cr | 7.25 Cr | 3.44 | 13.03 Cr | 0.0752 |
| 2020-03-31 | 84.87 Cr | 55.28 Cr | 29.59 Cr | 0.3487 | 0.00 Cr | 2.08 Cr | 4.52 Cr | 1.85 Cr | 0.88 | 6.24 Cr | 0.0218 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1.71 Cr | 182.37 Cr | 30.46 Cr | 151.9096 Cr | 5.25 Cr | 3.54 Cr | 13.67 Cr | 11.41 Cr | 6.44 Cr | 0.00 Cr | 9.92 Cr | 28.3165 Cr |
| 2023-03-31 | 8.81 Cr | 167.27 Cr | 32.69 Cr | 134.5775 Cr | 2.30 Cr | -6.51 Cr | 12.64 Cr | 6.96 Cr | 0.00 Cr | 0.00 Cr | -63.72 Cr | 29.6325 Cr |
| 2022-03-31 | 1.58 Cr | 155.24 Cr | 33.51 Cr | 121.7312 Cr | 5.85 Cr | 4.27 Cr | 15.46 Cr | 9.22 Cr | 0.00 Cr | 0.00 Cr | -61.23 Cr | 31.3834 Cr |
| 2021-03-31 | 1.80 Cr | 140.37 Cr | 32.73 Cr | 107.6413 Cr | 0.19 Cr | -1.61 Cr | 16.56 Cr | 8.73 Cr | 0.00 Cr | 0.00 Cr | -30.54 Cr | 32.7179 Cr |
| 2020-03-31 | 4.97 Cr | 121.35 Cr | 20.98 Cr | 100.3725 Cr | 0.41 Cr | -4.56 Cr | 12.55 Cr | 7.22 Cr | 0.00 Cr | 0.00 Cr | -22.01 Cr | 20.7867 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3.6487 Cr | -13.3357 Cr | 2.5832 Cr | -2.7365 Cr | -5.7038 Cr | 3.1101 Cr | -6.3852 Cr | 16.7765 Cr | 2.9424 Cr | 0.0000 Cr | -1.0241 Cr |
| 2023-03-31 | 8.9044 Cr | 2.1275 Cr | -3.7932 Cr | 7.7784 Cr | 7.2387 Cr | 8.8139 Cr | -1.1260 Cr | 15.6805 Cr | -3.5696 Cr | 0.0000 Cr | 2.8224 Cr |
| 2022-03-31 | 9.9403 Cr | -15.6096 Cr | 5.4425 Cr | 7.7494 Cr | -8.9348 Cr | 1.5752 Cr | -2.1909 Cr | 19.5601 Cr | 5.6616 Cr | 0.0000 Cr | 1.0962 Cr |
| 2021-03-31 | -1.7000 Cr | 5.8600 Cr | 0.1900 Cr | -4.9200 Cr | 4.3403 Cr | 10.5100 Cr | -3.2200 Cr | 10.7900 Cr | 0.2700 Cr | 0.0000 Cr | -4.0093 Cr |
| 2020-03-31 | 17.7820 Cr | -11.1623 Cr | -1.3492 Cr | 15.2367 Cr | 5.2706 Cr | 6.1697 Cr | -2.5453 Cr | 2.9075 Cr | -1.2724 Cr | 0.0000 Cr | 1.4882 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 26.15 Cr | 16.18 Cr | 9.97 Cr | 0.3813 | 0.19 Cr | 8.90 Cr | 4.23 | 9.54 Cr | 0.3404 |
| 2024-09-30 | 24.94 Cr | 16.10 Cr | 8.84 Cr | 0.3546 | 2.79 Cr | 7.69 Cr | 3.66 | 10.23 Cr | 0.3082 |
| 2024-06-30 | 21.44 Cr | 18.89 Cr | 2.55 Cr | 0.1190 | -0.01 Cr | 5.10 Cr | 2.42 | 5.69 Cr | 0.2377 |
| 2024-03-31 | 23.61 Cr | 16.85 Cr | 6.76 Cr | 0.2864 | 2.98 Cr | 3.54 Cr | 1.71 | 7.49 Cr | 0.1498 |
| 2023-12-31 | 27.31 Cr | 21.97 Cr | 5.34 Cr | 0.1955 | 1.77 Cr | 4.51 Cr | 2.17 | 5.98 Cr | 0.1651 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 0.11 Cr | 110.48 Cr | 110.59 Cr | 0.00 Cr | 14.72 Cr | 177.37 Cr | 10.89 Cr | 198.97 Cr | 34.36 Cr |
| 2024-03-31 | 1.71 Cr | 91.14 Cr | 92.85 Cr | 41.73 Cr | 13.67 Cr | 160.74 Cr | 11.41 Cr | 182.37 Cr | 30.46 Cr |
| 2023-12-31 | -102.05 Cr | 204.11 Cr | 102.05 Cr | 0.00 Cr | 0.00 Cr | 102.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 2.41 Cr | 106.14 Cr | 102.05 Cr | 40.19 Cr | 12.60 Cr | 167.74 Cr | 6.93 Cr | 183.90 Cr | 40.58 Cr |
| 2023-06-30 | -82.18 Cr | 164.36 Cr | 82.18 Cr | 0.00 Cr | 0.00 Cr | 82.18 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3.55 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 4.51 Cr | 1.32 Cr | 0.00 Cr | 0.00 Cr | 1.32 Cr | 3.74 Cr | 2.41 Cr | 0.00 Cr | 1.32 Cr |
| 2023-09-30 | 5.79 Cr | 0.99 Cr | 0.00 Cr | 0.00 Cr | 0.99 Cr | 2.41 Cr | 1.43 Cr | 0.00 Cr | 0.99 Cr |
| 2023-06-30 | 3.03 Cr | 0.55 Cr | 0.00 Cr | 0.00 Cr | 0.55 Cr | 9.36 Cr | 8.81 Cr | 0.00 Cr | 0.55 Cr |
| 2023-03-31 | 4.60 Cr | 1.06 Cr | 0.00 Cr | 0.00 Cr | 1.06 Cr | 8.81 Cr | 7.75 Cr | 0.00 Cr | 1.06 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,675.70 | ₹4,020,473,496,000.00 | ₹2,160,156.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,809.50 | ₹1,807,711,155,500.00 | ₹599,616.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,408.20 | ₹1,153,488,249,000.00 | ₹2,210,812.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,283.30 | ₹1,067,807,930,342.00 | ₹2,224,032.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹989.95 | ₹996,117,388,500.00 | ₹818,641.00 |
| Mankind Pharma Limited | MANKIND | ₹2,319.80 | ₹957,448,177,448.00 | ₹242,516.00 |
| Lupin Limited | LUPIN | ₹1,938.00 | ₹885,074,910,000.00 | ₹747,405.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,134.80 | ₹659,094,109,600.00 | ₹1,653,538.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,939.00 | ₹590,531,535,000.00 | ₹71,581.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,753.80 | ₹494,924,113,800.00 | ₹925,570.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Laurus Labs Limited | LAURUSLABS | ₹724.85 | ₹390,877,537,050.00 | ₹4,837,288.00 |
| Cohance Lifesciences Limited | COHANCE | ₹967.90 | ₹370,286,607,043.00 | ₹533,262.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,389.80 | ₹352,597,819,200.00 | ₹334,888.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,574.10 | ₹321,535,979,200.00 | ₹131,475.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,714.00 | ₹278,489,006,000.00 | ₹1,320,711.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,679.30 | ₹262,069,878,700.00 | ₹1,260,647.00 |
| Piramal Enterprises Limited | PEL | ₹1,144.20 | ₹259,364,967,600.00 | ₹439,580.00 |
| Eris Lifesciences Limited | ERIS | ₹1,683.80 | ₹229,328,508,600.00 | ₹146,873.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,908.50 | ₹222,712,500,000.00 | ₹41,092.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹1,039.10 | ₹204,248,613,300.00 | ₹15,274,048.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,210.60 | ₹192,825,578,600.00 | ₹542,905.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹926.65 | ₹165,972,281,500.00 | ₹2,317,809.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,117.60 | ₹160,962,375,920.00 | ₹209,291.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,000.00 | ₹153,958,800,000.00 | ₹31,199.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹495.30 | ₹120,181,573,200.00 | ₹480,052.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,880.50 | ₹97,612,771,700.00 | ₹5,473.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹890.55 | ₹87,087,685,995.00 | ₹84,311.00 |
| Strides Pharma Science Limited | STAR | ₹899.65 | ₹82,914,173,055.00 | ₹451,712.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹890.35 | ₹80,696,533,917.00 | ₹509,474.00 |
| FDC Limited | FDC | ₹487.50 | ₹79,369,875,000.00 | ₹123,391.00 |
| Suven Life Sciences Limited | SUVEN | ₹246.15 | ₹53,678,915,100.00 | ₹185,211.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹162.39 | ₹52,699,127,580.00 | ₹588,486.00 |
| Innova Captab Limited | INNOVACAP | ₹858.75 | ₹49,141,908,638.00 | ₹33,627.00 |
| Sequent Scientific Limited | SEQUENT | ₹192.75 | ₹48,246,288,750.00 | ₹444,510.00 |
| Hikal Limited | HIKAL | ₹358.90 | ₹44,252,728,900.00 | ₹296,200.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹458.15 | ₹41,815,350,500.00 | ₹289,887.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹589.30 | ₹41,490,137,940.00 | ₹13,357.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,480.80 | ₹41,029,951,200.00 | ₹30,790.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹364.05 | ₹36,506,205,900.00 | ₹138,450.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹714.30 | ₹36,228,653,130.00 | ₹50,530.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹61.77 | ₹33,847,118,580.00 | ₹4,023,013.00 |
| Alembic Limited | ALEMBICLTD | ₹121.80 | ₹31,276,047,478.00 | ₹6,054,805.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹637.05 | ₹30,675,868,650.00 | ₹262,587.00 |
| Indoco Remedies Limited | INDOCO | ₹317.60 | ₹29,297,933,040.00 | ₹135,261.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹97.19 | ₹28,527,889,130.00 | ₹1,241,703.00 |
Key Executives
Additional Whole Time Director
Mr. Shitul Shah
Gender: male
Year Born: 1979
Chief Financial Officer
Mr. Bakulesh Chandulal Shah
Gender: male
Year Born: 1961
Company Secretary & Compliance Officer
Ms. Srashti Chopra
Gender: female
Year Born:
Chairman of the Board
Mr. Mahendra Singh Chawla
Gender: male
Year Born: 1942
Executive Director
Mr. Vitthal Kothana
Gender: male
Year Born: 1957
Executive Director
Mr. Pravin C. Shah
Gender: male
Year Born: 1948
MD & Director
Mr. Paresh Chawla
Gender: male
Year Born: 1975
FAQs about Alpa Laboratories Limited
Who is the CEO of the company?
The CEO is Mr. Mahendra Singh Chawla.
What is the current market price of the stock?
The current price is ₹99.97.
What is the 52-week price range?
The range is ₹83-144.5.
What is the market capitalization of the company?
The market capitalization is ₹210.34 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 8.34.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alpa Laboratories Limited (ISIN: INE385I01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹210.34 crores and an average daily volume of 41,581 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.